Mesenchymal-Stem-Cell-Based Therapy against Gliomas

Cells. 2024 Apr 2;13(7):617. doi: 10.3390/cells13070617.

Abstract

Glioblastoma is the most aggressive, malignant, and lethal brain tumor of the central nervous system. Its poor prognosis lies in its inefficient response to currently available treatments that consist of surgical resection, radiotherapy, and chemotherapy. Recently, the use of mesenchymal stem cells (MSCs) as a possible kind of cell therapy against glioblastoma is gaining great interest due to their immunomodulatory properties, tumor tropism, and differentiation into other cell types. However, MSCs seem to present both antitumor and pro-tumor properties depending on the tissue from which they come. In this work, the possibility of using MSCs to deliver therapeutic genes, oncolytic viruses, and miRNA is presented, as well as strategies that can improve their therapeutic efficacy against glioblastoma, such as CAR-T cells, nanoparticles, and exosomes.

Keywords: CAR-T; exosomes; glioblastoma; mesenchymal stem cells; nanoparticles; tropism.

Publication types

  • Review

MeSH terms

  • Brain Neoplasms* / metabolism
  • Glioblastoma* / metabolism
  • Glioma* / metabolism
  • Humans
  • Mesenchymal Stem Cell Transplantation*
  • Mesenchymal Stem Cells* / metabolism

Grants and funding

This work was partially supported by grant 18/21 from the University of Navarra Foundation, Pamplona, Spain, to J.S.C.